Tempus AI has launched an upgraded version of its Lens platform, designed to enhance drug development processes by integrating a vast multimodal dataset with specialized AI agents. This next-generation agentic AI platform aims to significantly reduce the time required for designing clinical trials and generating supporting evidence, thereby increasing efficiency in the drug development pipeline.

Lens: Lens is Tempus AI’s agentic AI platform designed to connect large multimodal datasets with intelligent agents for healthcare applications. It supports tasks such as clinical trial optimization and evidence synthesis in drug development. The platform’s latest version directly addresses efficiency in trial design processes as announced in the current release.
Tempus AI: Tempus AI is a precision medicine company that builds AI-driven platforms to analyze multimodal healthcare data for oncology and other therapeutic areas. It focuses on integrating clinical, molecular, and imaging information to support research and development efforts. The company has launched an upgraded Lens platform to accelerate drug trial design and real-world evidence generation using specialized AI agents.

AI Platform Launch: Tempus AI has released an upgraded agentic version of its Lens platform tailored for multimodal data integration in drug development.
Drug Development Efficiency: Specialized AI agents are being applied to reduce timelines associated with designing clinical trials and producing supporting evidence.